Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Etripamil (Primary)
- Indications Paroxysmal supraventricular tachycardia
- Focus Adverse reactions; Registrational
- Sponsors Milestone Pharmaceuticals
- 08 Jan 2019 Status changed from not yet recruiting to recruiting.
- 26 Nov 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 26 Nov 2018 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2021.